Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Schott

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancerRachel M Layman, Dafydd G Thomas, Kent A Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast CancerRobert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
Plos One|March 28, 2015
Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapyCraig J Galbán, Bing Ma, Dariya Malyarenko, et al.
Breast Cancer Research and Treatment|July 10, 2016
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancerZ A Nahleh, W E Barlow, D F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500Jeffrey B Smerage, William E Barlow, Gabriel N Hortobagyi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumorsAnne F Schott, Melissa D Landis, Gabriela Dontu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2017
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202N Lynn Henry, Joseph M Unger, Anne F Schott, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancerCostanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
Science Translational Medicine|November 1, 2016
Cancer cells induce metastasis-supporting neutrophil extracellular DNA trapsJuwon Park, Robert W Wysocki, Zohreh Amoozgar, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancerRachel M Layman, Dafydd G Thomas, Kent A Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast CancerRobert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
Plos One|March 28, 2015
Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapyCraig J Galbán, Bing Ma, Dariya Malyarenko, et al.
Breast Cancer Research and Treatment|July 10, 2016
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancerZ A Nahleh, W E Barlow, D F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500Jeffrey B Smerage, William E Barlow, Gabriel N Hortobagyi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumorsAnne F Schott, Melissa D Landis, Gabriela Dontu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2017
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202N Lynn Henry, Joseph M Unger, Anne F Schott, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancerCostanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
Science Translational Medicine|November 1, 2016
Cancer cells induce metastasis-supporting neutrophil extracellular DNA trapsJuwon Park, Robert W Wysocki, Zohreh Amoozgar, et al.
Pageof 7